文献速递病毒性肝炎

直接抗病毒药物治疗丙型肝炎可降低新发糖尿病风险:ERCHIVES队列研究结果

Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES).
PubMed 文献 · Clin Infect Dis · 2020-01-01

DAA治疗者糖尿病发生率为9.89/1000人年,显著低于未治疗者的20.6/1000人年(P<.001)。DAA治疗(HR 0.53)和持续病毒学应答(HR 0.81)与糖尿病风险显著降低相关,肝纤维化越严重者获益越明显。

要点

  • DAA治疗者糖尿病发生率为9.89/1000人年,显著低于未治疗者的20.6/1000人年。
  • DAA治疗(HR 0.53)和持续病毒学应答(HR 0.81)与糖尿病风险显著降低独立相关。
  • 肝纤维化越严重(FIB-4>3.25),DAA治疗降低糖尿病风险的绝对差值越大(9.8)。

核心结论

  • DAA治疗显著降低慢性HCV感染者后续糖尿病的发生率和风险,且肝纤维化越严重者获益越明显。

研究设计与样本

  • 排除基线糖尿病、HIV或HBV合并感染者及同时接受PEG/RBV和DAA治疗者,并按年龄、种族、性别和倾向评分1:1匹配对照。

主要发现

  • 糖尿病发生率(每1000人年)为未治疗者20.6(95%CI 19.6-21.6)、PEG/RBV治疗者19.8(95%CI 18.3-21.4)、DAA治疗者9.89(95%CI 8.7-11.1),P<.001。
  • 治疗者中,获得持续病毒学应答(SVR)者糖尿病发生率为13.3(95%CI 12.2-14.5),未获得SVR者为19.2(95%CI 17.4-21.1),P<.0001。
  • DAA治疗(HR 0.53,95%CI .46-.63)和SVR(HR 0.81,95%CI .70-.93)与糖尿病风险显著降低相关。
  • 肝纤维化越严重,DAA治疗降低糖尿病风险的绝对差值越大:FIB-4<1.25为2.9,FIB-4 1.26-3.25为5.7,FIB-4>3.25为9.8。
  • DAA治疗者无糖尿病生存率长于未治疗者和PEG/RBV治疗者,而未治疗者与PEG/RBV治疗者间无显著差异。

临床怎么用

  • 对慢性HCV感染者,尤其是肝纤维化较严重者,DAA治疗可能同时降低新发糖尿病风险。
  • 获得持续病毒学应答(SVR)与糖尿病风险降低相关,支持以治愈HCV为目标的治疗策略。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effects of interferon-based therapies for hepatitis C virus (HCV) upon the risk of diabetes are controversial. The effects of newer, directly acting antiviral agents (DAA) upon this risk are unknown. We sought to determine the effects of HCV treatment upon the risk and incidence of diabetes. METHODS: Using the Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES) database for persons with chronic HCV infection (n = 242 680), we identified those treated with a pegylated interferon and ribavirin regimen (PEG/RBV, n = 4764) or a DAA-containing regimen (n = 21 279), after excluding those with diabetes at baseline, those with a human immunodeficiency virus or hepatitis B virus coinfection, and those treated with both PEG/RBV and DAA regimens. Age-, race-, sex-, and propensity score-matched controls (1:1) were also identified. RESULTS: Diabetes incidence rates per 1000 person-years were 20.6 (95% confidence interval [CI] 19.6-21.6) among untreated persons, 19.8 (95% CI 18.3-21.4) among those treated with PEG/RBV, and 9.89 (95% CI 8.7-11.1) among DAA-treated persons (P < .001). Among the treated, rates were 13.3 (95% CI 12.2-14.5) for those with a sustained virologic response (SVR) and 19.2 (95% CI 17.4-21.1) for those without an SVR (P < .0001). A larger reduction was observed in persons with more advanced fibrosis/cirrhosis (absolute difference 2.9 for fibrosis severity score [FIB-4] < 1.25; 5.7 for FIB-4 1.26-3.25; 9.8 for FIB-4 >3.25). DAA treatment (hazard ratio [HR] 0.53, 95% CI .46-.63) and SVR (HR 0.81, 95% CI .70-.93) were associated with a significantly reduced risk of diabetes. DAA-treated persons had longer diabetes-free survival rates, compared to untreated and PEG/RBV-treated persons. There was no significant difference in diabetes-free survival rates between untreated and PEG/RBV-treated persons. The results were similar in inverse probability of treatment and censoring weight models. CONCLUSIONS: DAA therapy significantly reduces the incidence and risk of subsequent diabetes. Treatment benefits are more pronounced in persons with more advanced liver fibrosis.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Butt AA, Yan P, Aslam S, et al. Hepatitis C Virus (HCV) Treatment With Directly Acting Agents Reduces the Risk of Incident Diabetes: Results From Electronically Retrieved Cohort of HCV Infected Veterans (ERCHIVES). Clin Infect Dis. 2020. PMID: 30977808. doi:10.1093/cid/ciz304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。